Anticorps Monoclonal anti-NeutraKine® IL-17A

NeutraKine® IL-17A Monoclonal Antibody for Neutralization, ELISA

Hôte / Isotype

Mouse / IgG1

Réactivité testée

Humain

Applications

Neutralization, ELISA, Cell treatment

Conjugaison

Non conjugué

Publications(3)

CloneNo.

1F3E3

N° de cat : 69021-1-Ig

Synonymes

IL 17, IL17, IL-17, IL17A, 1F3E3

---

Galerie de données de validation

• 

  Neutralization experiment of NeutraKine® IL-17A using 69021-1-Ig

  Recombinant human IL-17A (Cat.NO. HZ-1113) stimulates HT-1080 cells (human fibroblast cell line) produce IL-6 in a dose dependent manner (blue curve, refer to bottom X-Left Y axis). The activity of human IL-17A (40ng/mL HZ-1113) is neutralized by mouse anti-human IL-17A monoclonal antibody 69021-1-Ig (red curve, refer to top X-right Y axis). The ND50 is typically 200-600ng/mL.

• 

  Neutralization experiment of NeutraKine® IL-17A using 69021-1-Ig

  Recombinant human IL-17A (Cat.NO. HZ-1113) stimulates HT-1080 cells (human fibroblast cell line) produce IL-6 in a dose dependent manner (blue curve, refer to bottom X-Left Y axis). The activity of human IL-17A (40ng/mL HZ-1113) is neutralized by mouse anti-human IL-17A monoclonal antibody 69021-1-Ig (red curve, refer to top X-right Y axis). The ND50 is typically 200-600ng/mL. The NeutraControl mouse anti-human IL-17A monoclonal antibody 69521-1-Ig could recognize human IL-17A, but could not neutralize human IL-17A at the range of 0.3051-5 μg/mL(green curve, refer to top X-right Y axis).

• 

  ELISA experiment of Recombinant protein using 69021-1-Ig

  Indirect ELISA was carried out by coating recombinant Human IL-17A (Cat.NO. HZ-1113) at 70 ng/well followed by blocking and adding serial diluted IL-17A antibody 69021-1-Ig and 69521-1-Ig respectively. Signal was developed with TMB and stopped by H2SO4. Signal strength was measured by absorbance at 450 nm.

---

• Neutralization: cellule HT-1080

Informations sur le produit

69021-1-Ig cible NeutraKine® IL-17A dans les applications de Neutralization, ELISA, Cell treatment et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Réactivité citée: Humain
• Hôte / Isotype: Mouse / IgG1
• Clonalité: Monoclonal
• Type: Anticorps
• Immunogène: human Humankine IL-17A protein HZ-1113
• Nom complet: interleukin 17A
• Symbole du gène: IL-17A
• Identification du gène (NCBI): 3605
• Conjugaison: Non conjugué
• Forme: Lyophilized Powder
• Méthode de purification: Purification par protéine G
• Tampon de stockage: Sterile PBS
• Endotoxin: <0.1 EU/μg
• Reconstitution: This product was lyophilized from a 0.2 μm filtered solution in PBS. Reconstitute at 1.0 mg/mL in sterile H2O before use.
• Stability and Storage: Lyophilized antibodies are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products.

Informations générales

IL17A, also named as IL-17, is a proinflammatory cytokine. IL-17, synthesized only by memory T cells and natural killer cells, has pleiotropic effects, mainly in the recruitment and activation of neutrophils. This cytokine regulates the activities of NF-kappaB and mitogen-activated protein kinases. This cytokine can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO). High levels of this cytokine are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis. The IL-17 receptor is a type I transmembrane protein, that is widely expressed on epithelial cells, fibroblasts, B and T cells, and monocytic cells. In psoriatic skin lesions, both Th17 cells and their downstream effector molecules, e.g. IL-17 and IL-22, are highly increased.

This antibody can be used to neutralize the bioactivity of IL-17A.

Publications

Species	Application	Title
	Neutralization	Int J Chron Obstruct Pulmon Dis; IL-17A Promotes Epithelial ADAM9 Expression in Cigarette Smoke-Related COPD; Authors - Danyang Li
human	Cell treatment	JCI Insight; Targeting mTOR with a sirolimus-eluting airway stent reduces pro-fibrotic TH17-cells and inhibits laryngotracheal stenosis; Authors - Kevin M Motz
	Neutralization	Cell Mol Gastroenterol Hepatol; Fatty Acid Oxidation Promotes Apoptotic Resistance and Proinflammatory Phenotype of CD4+ Tissue-resident Memory T cells in Crohn's Disease; Authors - Guanzhan Liang

{{ptg:RelatedPrimaryAntibodies}}